[Skip to Content]
[Skip to Content Landing]
April 9, 2008

Expanding the Treatment Options for Hepatocellular CarcinomaCombining Transarterial Chemoembolization With Radiofrequency Ablation

Author Affiliations

Author Affiliations: Massachusetts General Hospital Cancer Center, and Harvard Medical School, Boston, Massachusetts (Dr Zhu); and Memorial Sloan-Kettering Cancer Center, New York, New York (Dr Abou-Alfa).

JAMA. 2008;299(14):1716-1718. doi:10.1001/jama.299.14.1716

Hepatocellular carcinoma (HCC) represents a challenging malignancy of worldwide importance: it is the sixth most common cancer and the third most common cause of cancer-related death globally.1 The incidence rates for HCC in the United States and Western Europe have been increasing.2,3 Despite many efforts in prevention and screening for HCC, only 20% to 30% of patients present with early stage disease amenable to curative treatments, including surgical resection and liver transplantation.4,5 Although many interventional-based treatment options are available for unresectable HCC, the benefits and limitations of these individual treatment approaches remain controversial.

First Page Preview View Large
First page PDF preview
First page PDF preview